Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 50,000 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. acquired 50,000 shares of the stock in a transaction dated Wednesday, January 7th. The stock was bought at an average price of $16.38 per share, for a total transaction of $819,000.00. Following the completion of the purchase, the chief executive officer owned 316,155 shares in the company, valued at approximately $5,178,618.90. This trade represents a 18.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $16.08 on Friday. The business has a 50 day simple moving average of $34.94 and a 200 day simple moving average of $24.01. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The company has a market capitalization of $863.17 million, a PE ratio of -2.27 and a beta of -1.45. Zenas BioPharma, Inc. has a one year low of $5.83 and a one year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ZBIO shares. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $37.00 to $19.00 in a report on Monday, January 5th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Evercore ISI assumed coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma currently has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Quarry LP boosted its position in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Zenas BioPharma during the third quarter valued at $30,000. BNP Paribas Financial Markets lifted its stake in shares of Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Zenas BioPharma in the second quarter worth about $118,000.

Zenas BioPharma News Summary

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon O. Moulder Jr. bought a total of ~100,000 shares across Jan. 7–9 (aggregate ≈ $1.63M), increasing his stake to 366,155 shares — a strong insider-buy signal that typically supports near-term buying interest. Read More.
• Positive Sentiment: Brokerages have assigned a consensus rating of “Moderate Buy” for ZBIO, which can attract institutional and retail demand if the view is publicized and reinforced. Read More.
• Neutral Sentiment: Multiple SEC filings disclose the CEO purchases (detailed trade dates and average prices), confirming the insider transactions are official, transparent, and recently reported. Read More.
• Negative Sentiment: Pomerantz LLP issued an investor alert announcing an investigation into Zenas BioPharma, which creates litigation risk and may increase volatility or prompt selling pressure until details clarify. Read More.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.